Clear Cell Renal Cell Carcinoma
Key Points
Key Points
- Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
- Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
- This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).
Diagnosis
...iagnos...
...1.1The diagnosis of metastatic clear...
...ecommendation 1.2Radiographic diagno...
Treatment
...reatme...
...ation 2.1Select patients (see Practical Informatio...
...on 3.1Select patients with metastati...
...First-Line Treatmenta Select cases (see Rec...
...n 3.2All patients with metastatic c...
...n 3.3Patients with favorable risk disease w...
...tion 3.4Select patients with metas...
Recommendation 3.5The use of high d...
...mmendation from 2023 Rapid Recommendation Update...
...ecommendation 3.6Treatment with IpiNivoCabo is...
...ion 4.1Nivolumab or cabozantinib should be offe...
...ion 4.2Patients progressing on combination immun...
...ommendation 4.3Patients who progress after initial...
....4For patients on immunotherapy who experience li...
...mendation 5.1For patients with low vo...
...ecommendation 5.2For patients under...
...commendation 6.1.1Patients with sympt...
Recommendation 6.1.2Patients with bone metasta...
...Second-Line or Greater Treatment
...Metastases-Directed Treatment
...commendation 6.1.3No recommendation regarding opti...
...ation 6.2.1Patients with brain metastases from...
...on 6.2.2No recommendation regarding...
Recommendation 6.3Patients with metastatic clear...
...re 4. Special Patient S...
...ves that cancer clinical trials are vital to in...